Superworth

Impact Biomedical price to book ratio IBO

Market value divided by the book value of the company's net assets, since 2024.

Today, Nov 2, 2026
40.2×
2-year median
25.0×
Against its 2-year history
61st
percentile: 0 is its lowest day, 100 its highest
2-year range
2.8× to 84.1×
Peer median
2.0×

Impact Biomedical's price to book ratio is 40.2× as of Nov 2, 2026.

That is above its 2-year median of 25.0×, close to the middle of its last 2 years.

Over that time it ranged from 2.8× in Mar 2025 to 84.1× in Mar 2026.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far40.2×26.8×84.1×
202523.2×2.8×34.5×
20246.7×5.4×15.7×

Against its peers

Companies in Drug Manufacturers - General nearest Impact Biomedical's size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Impact Biomedical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.